Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
1.110
-0.060 (-5.13%)
Feb 6, 2025, 4:00 PM EST - Market closed
Prelude Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Prelude Therapeutics stock have an average target of 4.50, with a low estimate of 4.00 and a high estimate of 5.00. The average target predicts an increase of 305.41% from the current stock price of 1.11.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 11, 2024.
Analyst Ratings
The average analyst rating for Prelude Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $7 → $4 | Buy | Reiterates | $7 → $4 | +260.36% | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +350.45% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +350.45% | Oct 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $5 | Hold → Strong Buy | Upgrades | $5 | +350.45% | Sep 19, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $7 | Buy | Reiterates | $7 | +530.63% | Sep 16, 2024 |
Financial Forecast
Revenue This Year
2.30M
Revenue Next Year
n/a
from 2.30M
EPS This Year
-1.81
from -2.02
EPS Next Year
-1.53
from -1.81
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 3.2M | n/a | n/a | |||
| Avg | 2.3M | n/a | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.86 | -0.71 | -0.41 | |||
| Avg | -1.81 | -1.53 | -1.35 | |||
| Low | -1.74 | -1.99 | -1.90 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.